# reload+after+2024-01-23 18:47:53.270252
address1§221 Crescent Street
address2§Suite 401
city§Waltham
state§MA
zip§02453
country§United States
phone§617 272 4600
fax§617 272 4601
website§https://www.viridiantherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
fullTimeEmployees§86
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Barrett  Katz CMO, M.B.A., M.D.', 'age': 73, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 635616, 'exercisedValue': 0, 'unexercisedValue': 1299404}, {'maxAge': 1, 'name': 'Mr. Stephen F. Mahoney J.D., MBA', 'age': 52, 'title': 'CEO, President & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric N. Olson Ph.D.', 'title': 'Co-Founder & Chairman of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael R. Bristow M.D., Ph.D.', 'age': 78, 'title': 'Co-Founder & Member of the Scientific Advisory Board', 'yearBorn': 1945, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marvin H. Caruthers Ph.D.', 'age': 83, 'title': 'Co-Founder & Scientific Advisory Board Member', 'yearBorn': 1940, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Vahe  Bedian Ph.D.', 'title': 'Co-Founder & Scientific Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Seth  Harmon', 'title': 'Senior VP of Finance and Accounting, Principal Financial & Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas W. Beetham J.D., MBA', 'age': 54, 'title': 'Chief Operating Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rob  Henderson Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John A. Jordan', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§3
compensationRisk§10
shareHolderRightsRisk§6
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.062
priceToSalesTrailing12Months§3215.7778
currency§USD
dateShortInterest§1702598400
forwardEps§-4.22
exchange§NCM
quoteType§EQUITY
shortName§Viridian Therapeutics, Inc.
longName§Viridian Therapeutics, Inc.
firstTradeDateEpochUtc§1403098200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§27827f35-49d4-3201-9b6a-83eb59a34eda
gmtOffSetMilliseconds§-18000000
targetHighPrice§50.0
targetLowPrice§29.0
targetMeanPrice§39.33
targetMedianPrice§38.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§15
quickRatio§13.469
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
